Gliadel® & Temodar® - Prospective Study
Braintumor Website

Last Updated:9/12/2013 - This page reviewed and approved by Virginia Stark-Vance, M.D.

Combination therapy of Gliadel wafers and temozolomide: A prospective, multicenter study in 92 patients with newly diagnosed high-grade glioma

  • Duntze J, Litre CF, Eap C, et al. Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. Ann Surg Oncol. 2013;20(6):2065-2072.
PubMed citation

Objectives: Study the feasibility and effectiveness of a treatment associated surgery, intraoperative chemotherapy (carmustine wafers), and concomitant radiochemotherapy (temozolomide) for the management of newly diagnosed, high-grade gliomas.

Methods: Prospective multicenter study conducted in 17 French centers with a total of 92 patients with newly diagnosed malignant glioma treated by surgery, implanted carmustine wafers (Gliadel) followed by concomitant radiochemotherapy by temozolomide (Temodar). Clinical, imaging, and survival data were collected to study toxicity-induced adverse events and efficacy.

Results: A total of 20.6% presented with adverse events during surgery, potentially attributable to carmustine, including 5 severe infections. Afterwards, 37.2% of patients showed adverse events during radiochemotherapy and 40% during adjuvant chemotherapy by temozolomide. We report a 10.5-month median progression-free survival and an 18.8-month median overall survival. No significant statistical difference was observed according to age, Karnofsky Performance Scale, or grade of the tumor. A prognostic difference at the limit of the significance threshold was observed according to the extent of the resection.

Conclusions: Multimodal treatment associating implanted carmustine chemotherapy and concomitant radiochemotherapy with temozolomide seems to yield better survival rates than those usually described when carmustine or temozolomide are used alone independently from one another. These interesting results were obtained without increased adverse events and would need to be validated during a phase 3 study.


Click on the links below for more information on Gliadel® Wafer!



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites